Abstract: The present invention relates to the field glycosylation engineering of proteins. More particular, the present invention is directed to the glycosylation engineering of proteins to provide proteins with improved therapeutic properties, e.g., antibodies, antibody fragments, or a fusion protein that includes a region equivalent to the Fc region of an immunoglobulin, with enhanced Fc-mediated cellular cytotoxicity.
Type:
Grant
Filed:
May 28, 2010
Date of Patent:
January 14, 2014
Assignee:
Roche GlycArt AG
Inventors:
Pablo Umaña, Joël Jean-Mairet, M. Sean Bailey
Abstract: The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with fludarabine and/or mitoxantrone for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody with fludarabine and/or mitoxantrone.
Abstract: The present invention relates to the field glycosylation engineering of proteins. More particular, the present invention is directed to the glycosylation engineering of proteins to provide proteins with improved therapeutic properties, e.g., antibodies, antibody fragments, or a fusion protein that includes a region equivalent to the Fc region of an immunoglobulin, with enhanced Fc-mediated cellular cytotoxicity.
Type:
Grant
Filed:
May 28, 2010
Date of Patent:
January 7, 2014
Assignee:
Roche GlycArt AG
Inventors:
Pablo Umaña, Joël Jean-Mairet, M. Sean Bailey
Abstract: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human EGFR. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
Abstract: The present invention relates to bispecific antibodies against human ErbB-2 and against human C-met, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof.
Abstract: The present invention relates to polypeptide formulations with reduced viscosity and methods of making and using polypeptide formulations with reduced viscosity.
Type:
Application
Filed:
August 3, 2010
Publication date:
September 12, 2013
Applicant:
F. HOFFMANN-LA ROCHE AG (ROCHE GLYCART AG)
Inventors:
Tim Kamerzell, Sheryl Martin-Moe, Yuchang John Wang
Abstract: The present invention relates to humanized antibodies against human CDCP1 (anti-CDCP1 antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
Abstract: The present invention is directed to methods for identifying which patients diagnosed with cancer will most benefit from treatment with an anti-cancer therapy comprising an ADCC-enhanced antibody.
Abstract: The present invention relates to bispecific antibodies against human ErbB-1 and against human c-Met, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof.
Abstract: The present invention relates to humanized antibodies against human CDCP1 (anti-CDCP1 antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
Type:
Grant
Filed:
August 26, 2010
Date of Patent:
March 12, 2013
Assignee:
Roche Glycart AG
Inventors:
Johannes Auer, Birgit Bossenmaier, Guy Georges, Alexander Lifke, Ekkehard Moessner, Gerhard Niederfellner
Abstract: The present invention relates to the field of glycosylation engineering of proteins. More particularly, the present invention relates to nucleic acid molecules, including fusion constructs, having catalytic activity and the use of same in glycosylation engineering of host cells to generate polypeptides with improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
Type:
Grant
Filed:
January 22, 2004
Date of Patent:
February 5, 2013
Assignee:
Roche GlycArt AG
Inventors:
Pablo Umaña, Peter Bruenker, Claudia Ferrara, Tobias Suter
Abstract: Herein is reported a fusion polypeptide comprising i) at least one binding site, e.g. which comprises an antibody heavy chain variable domain and an antibody light chain variable domain, and which binds to an internalizing cell surface receptor, and ii) at least one pharmaceutically active compound, whereby the EC50-value of the binding pair that binds to an internalizing cell surface receptor determined at pH 5.5 is higher than the EC50-value of the same binding pair determined at pH 7.4 and its use for delivering a pharmaceutically active compound across the blood-brain-barrier.
Type:
Application
Filed:
April 18, 2012
Publication date:
November 8, 2012
Applicant:
Roche Glycart AG
Inventors:
Bernd Bohrmann, Per-Ola Freskgard, Adrian Hugenmatter, Erhard Kopetzki, Ekkehard Moessner, Jens Niewoehner, Hadassah Sumum Sade, Pablo Umaña
Abstract: The present invention provides antigen binding molecules (ABMs) which bind membrane-bound CEA, including ABMs with improved therapeutic properties, and methods of using the same.
Type:
Application
Filed:
February 29, 2012
Publication date:
October 4, 2012
Applicant:
Roche Glycart AG
Inventors:
Thomas U. Hofer, Ralf Hosse, Ekkehard Moessner, Pablo Umana
Abstract: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human EGFR. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
Abstract: The present invention relates to bispecific antibodies comprising a first antigen binding site specific for a death receptor and a second antigen binding site specific for a second antigen, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
Type:
Application
Filed:
September 27, 2010
Publication date:
July 19, 2012
Applicant:
Roche Glycart AG
Inventors:
Peter Bruenker, Claudia Ferrara Koller, Sandra Grau, Sylvia Herter, Christoph Lampert, Ekkehard Moessner, Pablo Umana, Inja Waldhauer
Abstract: The present invention relates to the field glycosylation engineering of proteins. More particular, the present invention is directed to the glycosylation engineering of proteins to provide proteins with improved therapeutic properties, e.g., antibodies, antibody fragments, or a fusion protein that includes a region equivalent to the Fc region of an immunoglobulin, with enhanced Fc-mediated cellular cytotoxicity.
Abstract: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human EGFR. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
Abstract: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human EGFR. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
Type:
Grant
Filed:
March 15, 2010
Date of Patent:
January 3, 2012
Assignee:
Roche GlycArt AG
Inventors:
Pablo Uma{tilde under (n)}a, Ekkehard Mössner
Abstract: The present invention relates to the field of glycosylation engineering of proteins. More particularly, the present invention relates to glycosylation engineering to generate proteins with improved therapeutic properties, including antibodies with increased antibody-dependent cellular cytotoxicity.
Type:
Application
Filed:
August 2, 2011
Publication date:
December 1, 2011
Applicant:
Roche GlycArt AG
Inventors:
Pablo UMAÑA, Jöel Jean-Mairet, James E. Bailey
Abstract: The present invention relates to the field glycosylation engineering of proteins. More particular, the present invention is directed to the glycosylation engineering of proteins to provide proteins with improved therapeutic properties, e.g., antibodies, antibody fragments, or a fusion protein that includes a region equivalent to the Fc region of an immunoglobulin, with enhanced Fc-mediated cellular cytotoxicity.
Type:
Application
Filed:
December 23, 2010
Publication date:
December 1, 2011
Applicant:
Roche GlycArt AG
Inventors:
Pablo UMANA, Joel Jean-Mairet, James E. Bailey